Gara Jalqabaatti › Sklerosis Baay’ee › Tennessee
Qorannoo klinikaalii Sklerosis Baay’ee Tennessee keessatti
Qorannoo 6 Sklerosis Baay’ee f Tennessee keessatti hirmaatuu jiru.
Magaalota Tennessee keessatti
Takkalaa qorannoo (Ingiliffa)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Hope Neurology, Knoxville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Neurology Clinic PC, Cordova
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07609719A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Franklin
- TG Therapeutics Investigational Trial Site, Knoxville
- TG Therapeutics Investigational Trial Site, Mount Juliet
- fi 2 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Alliance for Multispecialty Research Clinical, Knoxville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Hope Neurology- Site Number : 8400019, Knoxville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 60 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07325292A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Neurology Clinic PC, Cordova
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT07225504Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.